These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7692199)

  • 1. Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin's disease: possible synergy.
    Matthews JH
    Lancet; 1993 Oct; 342(8877):988. PubMed ID: 7692199
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor.
    Merdin A; Çakar MK; Dal MS; Mert D; Yıldız J; Başçı S; Bakırtaş M; Darçın T; Şahin D; Ulu BU; Yiğenoğlu TN; Batgi H; Tetik A; İskender D; Altuntaş F
    J Oncol Pharm Pract; 2020 Jun; 26(4):929-932. PubMed ID: 31822199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent G-CSF to maintain dose intensity of chemotherapy for Hodgkin's disease.
    Clarke K; Grigg A
    Leuk Lymphoma; 1995 Nov; 19(5-6):521-2. PubMed ID: 8590858
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
    J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease.
    Silvestri F; Fanin R; Velisig M; Barillari G; Virgolini L; Zaja F; Russo D; Baccarani M
    Tumori; 1994 Dec; 80(6):453-8. PubMed ID: 7534963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABVD in the treatment of Hodgkin's disease.
    Bonfante V; Santoro A; Viviani S; Valagussa P; Bonadonna G
    Semin Oncol; 1992 Apr; 19(2 Suppl 5):38-44; discussion 44-5. PubMed ID: 1384143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
    Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
    Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute promyelocytic leukemia following ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and radiotherapy for Hodgkin's disease.
    Amadori S; Papa G; Anselmo AP; Fidani P; Mandelli F; Biagini C
    Cancer Treat Rep; 1983 Jun; 67(6):603-4. PubMed ID: 6190561
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute myeloid leukemia following therapy of Hodgkin's disease with radiotherapy and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine).
    Lipton JH; Gospodarowicz M; Reingold S
    Hematol Oncol; 1996 Mar; 14(1):29-31. PubMed ID: 8613133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Male infertility caused by the chemotherapy of Hodgkin's disease: MOPP versus ABVD.
    Ragni G; Lombardi C; Santoro A; Bestetti O; Wyssling H
    Acta Eur Fertil; 1983; 14(3):221-2. PubMed ID: 6199937
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study.
    Minuk LA; Monkman K; Chin-Yee IH; Lazo-Langner A; Bhagirath V; Chin-Yee BH; Mangel JE
    Leuk Lymphoma; 2012 Jan; 53(1):57-63. PubMed ID: 21740297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of the treatment of Hodgkin's disease stage III and IV using the ABVD and BACOP programs].
    Leszko B; Słomkowski M; Przybyszewska M; Apel D; Pawelski S
    Acta Haematol Pol; 1986; 17(3-4):81-90. PubMed ID: 2438894
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children's Cancer Study Group.
    Fryer CJ; Hutchinson RJ; Krailo M; Collins RD; Constine LS; Hays DM; Heller RM; Davis PC; Nachman J; O'Brien RT
    J Clin Oncol; 1990 Dec; 8(12):1971-80. PubMed ID: 1700080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MOPP, ABVD, or both to treat Hodgkin's disease.
    Aisenberg AC
    N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680765
    [No Abstract]   [Full Text] [Related]  

  • 15. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group.
    Takenaka T; Mikuni C; Miura A; Sasaki T; Suzuki H; Hotta T; Hirano M; Fukuhara S; Sugiyama H; Nasu K; Dohi H; Kozuru M; Tomonaga M; Tajima K; Niimi M; Fukuda H; Mukai K; Shimoyama M
    Jpn J Clin Oncol; 2000 Mar; 30(3):146-52. PubMed ID: 10798542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin's disease. A case report.
    Joensuu H; Söderström KO; Nikkanen V
    Cancer; 1986 Oct; 58(7):1437-40. PubMed ID: 2427187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
    Chand VK; Link BK; Ritchie JM; Shannon M; Wooldridge JE
    Leuk Lymphoma; 2006 Apr; 47(4):657-63. PubMed ID: 16690524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of survival in Hodgkin's lymphoma.
    Canellos GP; Niedzwiecki D; Johnson JL
    N Engl J Med; 2009 Dec; 361(24):2390-1. PubMed ID: 20007568
    [No Abstract]   [Full Text] [Related]  

  • 19. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
    Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
    J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cardiogenic shock during polychemotherapy in a patient with Hodgkin's disease].
    Drzewoski J; Chojnowski K; Olszańska-Skorek T; Krykowski E
    Kardiol Pol; 1986; 29(8):555-9. PubMed ID: 2435945
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.